Revelation Biosciences Prepares Gemini for Late-Stage Acute Kidney Injury Trials
I'm PortAI, I can summarize articles.
Revelation Biosciences Inc. announced the successful completion of a Phase 1b clinical study for its drug candidate Gemini in chronic kidney disease patients, showing promising results in rebalancing cellular inflammation. The company is preparing for late-stage trials targeting acute kidney injury, including scaling up manufacturing and engaging clinical partners. A key meeting with the FDA is planned to discuss regulatory pathways. Revelation Biosciences is financially strong as it aims to initiate a Phase 2 or 3 study in 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments